ENDRA Life Sciences Inc. (NASDAQ:NDRA) CTO Michael Milos Thornton sold 18,750 shares of the business’s stock in a transaction that occurred on Monday, March 29th. The shares were sold at an average price of $2.37, for a total value of $44,437.50. Following the completion of the transaction, the chief technology officer now owns 274,960 shares of the company’s stock, valued at $651,655.20. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Michael Milos Thornton also recently made the following trade(s):
- On Wednesday, April 7th, Michael Milos Thornton sold 15,000 shares of ENDRA Life Sciences stock. The shares were sold at an average price of $2.53, for a total value of $37,950.00.
NASDAQ NDRA opened at $2.51 on Thursday. The stock has a market capitalization of $104.42 million, a price-to-earnings ratio of -1.36 and a beta of 1.60. The stock’s 50 day moving average price is $2.49 and its two-hundred day moving average price is $1.42. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.19 and a current ratio of 3.42. ENDRA Life Sciences Inc. has a 52 week low of $0.60 and a 52 week high of $3.10.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Worth Venture Partners LLC bought a new stake in shares of ENDRA Life Sciences during the 4th quarter worth approximately $247,000. K.J. Harrison & Partners Inc raised its stake in shares of ENDRA Life Sciences by 60.9% during the 4th quarter. K.J. Harrison & Partners Inc now owns 277,629 shares of the company’s stock worth $208,000 after purchasing an additional 105,129 shares in the last quarter. HN Saltoro Capital LP bought a new stake in shares of ENDRA Life Sciences during the 4th quarter worth approximately $145,000. Renaissance Technologies LLC bought a new stake in shares of ENDRA Life Sciences during the 4th quarter worth approximately $65,000. Finally, Virtu Financial LLC raised its stake in shares of ENDRA Life Sciences by 62.5% during the 3rd quarter. Virtu Financial LLC now owns 41,738 shares of the company’s stock worth $31,000 after purchasing an additional 16,057 shares in the last quarter. Hedge funds and other institutional investors own 2.84% of the company’s stock.
Separately, Zacks Investment Research cut ENDRA Life Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, January 20th.
ENDRA Life Sciences Company Profile
ENDRA Life Sciences Inc develops technology for clinical diagnostic ultrasound. It develops thermo-acoustic enhanced ultrasound technology that transmits sound waves, which bounce off tissues, organs, and blood for the treatment of nonalcoholic fatty liver disease, as well as temperature monitoring of thermoablative surgery, vascular imaging, and tissue perfusion.
Further Reading: How To Calculate Debt-to-Equity Ratio
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.